Exro Technologies Responds to Market Activity
CALGARY, AB, April 23, 2025 /CNW/ - Exro Technologies Inc. (TSX: EXRO) ("Exro" or the "Company"), a leading technology company specializing in power control solutions for electric vehicles and energy storage, at the request of CIRO today issued the following statement in response to recent trading activity in its common shares.
Exro confirms that it is not aware of any undisclosed material change to the Company's business or operations that would account for the recent increase in its share price and trading volume.
As previously disclosed, the Company continues to actively explore financing alternatives to support its business plan and remains focused on executing its strategic initiatives.
ABOUT EXRO TECHNOLOGIES INC.
Exro Technologies Inc., now expanded through the strategic acquisition of SEA Electric, is a leading clean technology company that has developed new-generation power control electronics. Its innovative suite of solutions, including Coil Driver™, Cell Driver™, and SEA-Drive®, expand the capabilities of electric motors and batteries and offer OEMs a comprehensive e-propulsion solution with unmatched performance and efficiency. Exro is reshaping global energy consumption, accelerating adoption towards a circular electrified economy by delivering more with less – minimum energy for maximum results.
For more information visit our website at www.exro.com.
To view our Corporate Presentation visit us at www.exro.com/investors
Visit us on social media @exrotech.
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified using terminology such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words, or statements that certain actions, events or results "may", "could", "would", "might", "will be taken", "occur" or "be achieved". Forward looking statements involve risks, uncertainties and other factors disclosed under the heading "Risk Factors" and elsewhere in the Company's filings with Canadian securities regulators, that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company's annual information form for the financial year ended December 31, 2024, and financial statements and related MD&A for the financial year ended December 31, 2024, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties, and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated, or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/exro-technologies-responds-to-market-activity-302436303.html
SOURCE Exro Technologies Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/23/c0970.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Hyland expands its presence in India with a new office in Hyderabad
This marks a significant milestone in the company's global expansion strategy; enables access to technical expertise while strengthening the company's ability to serve customers globally NEW DELHI and HYDERABAD, India , June 10, 2025 /PRNewswire/ — Hyland, the pioneer of The Content Innovation Cloud™, is celebrating the official opening of its new office in Hyderabad , marking a significant milestone in the company's global expansion strategy, and mission to deliver breakthrough innovations to customers across the Asia Pacific region. The grand opening ceremony, held on 9 June 2025 , was graced by the presence of the US Consul General for Hyderabad , Ms. Jennifer Larson . Located in the heart of Hyderabad's prestigious Hitech City, the new facility represents Hyland's strategic investment in advancing The Content Innovation Cloud and accelerating customer success throughout Asia Pacific . This expansion positions the company to leverage the region's exceptional talent pool to drive next-generation innovations that transform how organizations manage, process, and unlock value from their content. ' Hyderabad's world-class technology ecosystem makes it the ideal location to advance The Content Innovation Cloud and deliver transformative solutions to our Asia Pacific customers,' said Tim McIntire , CTO at Hyland. 'This expansion directly supports our innovation agenda, enabling us to develop cutting-edge capabilities that help customers streamline operations, enhance productivity, and drive digital transformation. We're honored to have US Consul General Jennifer Larson join us for this momentous occasion, highlighting the power of US-India partnerships in advancing technological innovation.' The Hyderabad office will serve as a hub for innovation and customer success, housing critical functions focused on advancing The Content Innovation Cloud and delivering exceptional customer outcomes. This will drive product development, enhance customer enablement programs, and expand support capabilities to ensure Asia Pacific customers maximize value from Hyland's platform and solutions. The new facility is actively recruiting top talent to fuel Hyland's innovation engine across several key areas: Software Development professionals to architect and build next-generation capabilities within The Content Innovation Cloud to architect and build next-generation capabilities within The Content Innovation Cloud Professional Services specialists to accelerate customer implementations and drive successful digital transformation initiatives to accelerate customer implementations and drive successful digital transformation initiatives Customer Success coordinators to ensure customers achieve measurable business outcomes and maximize their return on investment to ensure customers achieve measurable business outcomes and maximize their return on investment Cloud and Technical Support experts to deliver world-class support and optimize customer experiences across cloud environments Hyland's new Hyderabad office joins its existing Kolkata location, reinforcing the company's global reach while creating significant employment opportunities, driving growth and customer success across the APAC region. To explore Hyland career opportunities in India , please visit the company's careers page at About Hyland Hyland empowers organizations with unified content, process and application intelligence solutions, unlocking profound insights that fuel innovation. Trusted by thousands of organizations worldwide, including many of the Fortune 100, Hyland's solutions fundamentally redefine how teams operate and engage with those they serve. For more information on Hyland, our products and solutions, please visit Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
an hour ago
- Business Upturn
Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun
Zen Technologies shares are in focus today after introducing its Four-Barrel Rotary Machine Gun, designed for counter-drone and high-intensity combat operations. The weapon features a rapid firing rate of up to 3,500 rounds per minute and an electronically operated firing mechanism, positioning it as a cutting-edge solution in modern warfare. Zen Technologies (@ZenTechnologies) Four-Barrel Rotary Machine Gun Featuring a firing rate of up to 3,500 rounds/min and dependable electronic operation, it stands as the premier weapon for counter-drone operations and intense combat scenarios. — Alpha Defense™🇮🇳 (@alpha_defense) June 10, 2025 The stock opened at ₹2,030.90 and touched an intraday high of ₹2,057.90, before slipping to a low of ₹2,015.00. It remains significantly below its 52-week high of ₹2,627.00 but well above the 52-week low of ₹945.35. As of 11:50 AM, the shares were trading 0.56% higher at Rs 2,025.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Wire
an hour ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
